Comparing daily aspirin doses in high-risk MPN patients with aspirin resistance
Official title: Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk Myeloproliferative Neoplasms Patients With Aspirin Resistance
Run by Siriraj Hospital · NCT06740916 · Data updated 2026-11-12
This study is testing whether taking aspirin once a day or twice a day can help high-risk patients with blood disorders reduce the risk of blood clots.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Siriraj Hospital Academic / other |
| Locations | 1 site (Bangkok Noi, Bangkok) |
| Status | Recruiting |
| Started | December 12, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2030 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT06740916 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with Philadelphia-negative myeloproliferative neoplasms who show laboratory aspirin resistance.
✕Probably not a fit
Patients with active cancer, thrombocytopenia, or those not exhibiting aspirin resistance will likely not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the long-term efficacy of administering aspirin once daily versus twice daily in patients with myeloproliferative neoplasms (MPN) who exhibit laboratory aspirin resistance. It involves a prospective randomized design where eligible adult patients will be assigned to one of the two aspirin dosing regimens. Platelet function testing will be conducted at baseline, one month, and six months to assess aspirin resistance, while clinical outcomes related to thrombosis and side effects will be monitored for at least two years. The aim is to determine if increasing the aspirin dose can effectively reduce thrombotic events in this high-risk population.
Why it matters
Potential benefit: If successful, this study could provide a more effective aspirin dosing strategy to prevent thrombotic events in high-risk MPN patients.
How similar studies have gone: While there is limited data on this specific approach, studies on aspirin dosing in other populations have shown varying degrees of success, making this a potentially novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old Exclusion Criteria: * Concomitant other active malignancy or cured less than 6 months * Platelet count less than 50,000/microL * Receiving anticoagulant * Active peptic ulcer * Active bleeding or Planning to undergo procedure/operation with bleeding risk * No laboratory aspirin resistance with LTA method
Where it's running
-
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital
Bangkok Noi, Bangkok, Thailand Recruiting
Study contacts
- Study coordinator: Yingyong Chinthammitr, MD, RCPT, Thai board of hemato
- Email: dryingyong@gmail.com
- Phone: +66 + 0814264252
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Orally administered JBI-802 in certain blood cancers with high platelets
This study tests whether taking JBI-802 by mouth can be safe and helpful for adults with essential thrombocythemia or related blood cancers that involve high platelet counts.
-
Exercise training for people with myeloproliferative neoplasms
A 3-month individualized exercise program is tested to see if it improves quality of life and fitness for adults with myeloproliferative neoplasms.
-
MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.
Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.
-
Monalizumab treatment for patients with blood cancers undergoing stem cell transplantation
This study is testing if a new treatment called Monalizumab can help people with blood cancers like AML or MDS who are getting stem cell transplants by improving their immune response and reducing the chances of disease returning or complications.
-
Identifying MPN-Specific Immune Targets in Blood and Bone Marrow
This study tests whether certain T cells in adults with MPN can recognize MPN cells and what antigens those T cells target.
-
Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers
This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.